01:27 PM EDT, 06/10/2025 (MT Newswires) -- Eli Lilly ( LLY ) will only partner with telehealth firms that stop selling copycat versions of its weight-loss drug, Bloomberg reported Tuesday, citing Chief Financial Officer Lucas Montarce, speaking at a conference.

The company's recent agreements with Ro and LifeMD ( LFMD ) prohibit them from selling compounded versions of Lilly's Zepbound and Novo Nordisk's ( NVO ) Wegovy, Montarce said, according to the report.

Eli Lilly ( LLY ) didn't immediately reply to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 803.72, Change: +30.14, Percent Change: +3.90